Effect of valsartan combined with statins on coronary heart disease and its effect on BNP and CRP
10.3969/j.issn.1673-4130.2019.04.012
- VernacularTitle:缬沙坦联合他汀类药物治疗冠心病的效果分析
- Author:
Ping LI
1
;
Shaomin WANG
;
Junqing CHEN
;
Zigang LIU
;
Yixiong PANG
Author Information
1. 武汉科技大学附属孝感医院检验科
- Keywords:
valsartan;
atorvastatin;
coronary heart disease;
blood lipids;
coronary plaques
- From:
International Journal of Laboratory Medicine
2019;40(4):427-430,434
- CountryChina
- Language:Chinese
-
Abstract:
Objective Investigate the effect of valsartan combined with statins on coronary heart disease and its effect on BNP and CRP.Methods 92cases of patients with coronary heart disease were selected, which were treated in hospital from March 2015to March 2017, and were divided into the study group (46cases) and control group (46cases) .The patients of all two groups were treated with conventional treatment.The patients of control group were treated with valsartan (40mg/d, oral;if no hypotension after 3days of treatment, the dose increased to 80mg/d) , and on the basis of control group, the patients of study group were treated with atorvastatin calcium capsules (20mg/d, in 0.5hafter dinner) .The patients of two groups were all treated for 6months in a row.Compare the adverse reactions and changes of the levels of blood lipids, coronary plaques, BNP, CRP and LVEF of two groups.Results After the appropriate treatment, the TG, TC, LDL-C levels of the study group were significantly lower than those of the control group, and the HDL-C, LVEF levels of the study group were significantly higher than those of the control group (P<0.05);the lipid plaque, fibrous plaque, calcified plaque, mixed plaque levels of the study group were significantly lower than those of the control group (P<0.05);The BNP, CRP levels of the study group were significantly lower than those of the control group (P<0.05);There were acute myocardial infarction, unstable angina, heart failure and other adverse events occurred in both two groups, and the difference was statistically significant between the two groups (P<0.05) .Conclusion Valsartan combined with statins in the treatment of patients with coronary heart disease can improve blood lipid levels, reduce coronal plaque area, inhibit inflammatory response, which makes it worthy of clinical promotion.
